Our last update was September 17th, so now is a good time as we enter the 4th quarter for some quick notes LTRN- $19.90 area Our latest research at 17.50 was as high as 21.25 recently, and they continue to progress with more news out today on...
LTRN 17.50 Area 12 Month Target $48 The current market cap of LTRN, with the stock around $17 per share, is close to $125 million dollars based on 7.37 million shares outstanding. Managers and directors own 51% of fully diluted shares outstanding. Lantern collaborates with top academic and...
Time for some position updates. I will likely issue a new report within next 2-4 weeks to add to our portfolio. ATOM, TFFP, PRVB, INMB all looking strong. Under water in CRBP, TBIO, and SAMAW for now...
CRBP 2.50 Average entry $5 Analyst high target $40 77% drop on Tuesday as results of the Phase 3 trial were not much better than placebo group. This was unexpected by those running the trials and management. It is thought that perhaps the Immunosuppressive drugs that 84% of...
INMB at 9.40 1 day after report, high of 10.60 on 8/20 post report and now 9.20 low today I have a few more items to help understand what they are doing with their TNF Inhibitor science which targets Inflammation and Cytokine storm issues that cause...
INMB- Inmune Bio $9.65 area Investing Advice: Buy from 9.50-10.50 ranges to accumulate a position Target is $25 plus in 6-12 months (Back to recent highs) Trading below the recent $10 secondar y offering and a gap fill area completed, this is the Tipping Point to buy the stock...
TFFP announced their quarterly update yesterday and the stock rallied as high as $14 post close from $10.28 52 week highs afterwards. They announced a worldwide licensing agreement for Niclosamide with Union Therapeutics. This is transformational and has 210 million in milestone payments, royalties, and...
Quick notes PRVB is back over 12 now after hitting 10.20 area last week. I posted on Stocktwits then I felt we hit a long term bottom and would march to 18 plus into the BLA application for Teplizumab. This is a good time to buy...
VIR- Closing out here at 46 area for 55% final gains on final 1/2 OTRK- Closing out final half here for 140% gains on final 1/2...
TBIO $16.30 area down from $28.09 highs in June on Sanofi news Tipping point to buy the stock after material drop following great news. Looks purely technical related and comes with insider buying.- Dave 67 Million shares outstanding, 1.1 billion market cap, 700 million cash. Translate Bio is...
indian xxnx horny desi indian cheating slime wife show boobs in webcam.
